American Journal of Cardiology
Volume 103, Issue 6 , Pages 867-871, 15 March 2009

Association of Uric Acid With Inflammation, Progressive Renal Allograft Dysfunction and Post-Transplant Cardiovascular Risk

  • Farah Bandukwala, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  • ,
  • Michael Huang, MSc

      Affiliations

    • Renal Transplant Program, St. Michael's Hospital, Toronto, Ontario, Canada
  • ,
  • Jeffrey S. Zaltzman, MD

      Affiliations

    • Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    • Renal Transplant Program, St. Michael's Hospital, Toronto, Ontario, Canada
  • ,
  • Michelle M. Nash, MSc

      Affiliations

    • Renal Transplant Program, St. Michael's Hospital, Toronto, Ontario, Canada
  • ,
  • G.V. Ramesh Prasad, MBBS

      Affiliations

    • Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    • Renal Transplant Program, St. Michael's Hospital, Toronto, Ontario, Canada
    • Corresponding Author InformationCorresponding author: Tel: 416-867-3722; fax: 416-867-3709

Received 7 July 2008; received in revised form 13 November 2008; accepted 13 November 2008. published online 27 January 2009.

Hyperuricemia is common after kidney transplantation. Although its risk factors are well established, its relation to inflammation, progressive renal dysfunction, and cardiovascular events is unknown. In this study, 405 stable renal transplant recipients with ≥3 uric acid (UA) and C-reactive protein measurements from January 2005 to April 2008 were identified to determine the relations between UA and C-reactive protein and between UA and the rate of decrease in the estimated glomerular filtration rate (eGFR; using the Modification of Diet in Renal Disease equation) and cardiovascular events. Hyperuricemia was defined as UA >7.1 mg/dl (420 μmol/L) in men and >6.1 mg/dl (360 μmol/L) in women. The prevalence of hyperuricemia was 44% (180 of 405). Hyperuricemia was negatively associated with eGFR (p <0.0001) and positively associated with diuretic use (p = 0.013), time since transplantation (p = 0.014), and triglycerides (p = 0.04). Although UA was correlated with C-reactive protein (p = 0.003), adjustment for eGFR rendered this relation nonsignificant (p = 0.225). The slope of eGFR was +0.144 ± 0.85 ml/min/1.73 m2/month (95% confidence interval 0.032 to 0.257) in those with normal UA levels and −0.091 ± 0.93 ml/min/1.73 m2/month (95% confidence interval −0.235 to +0.054) in patients with hyperuricemia (p = 0.003). There were 17 cardiovascular events in the patients with hyperuricemia and 4 in those with normal UA levels (p = 0.001). In conclusion, hyperuricemia is associated with a decrease in renal allograft function and may be an independent cardiovascular risk factor in transplant recipients. Further studies are needed to establish its role in post-transplantation cardiovascular disease.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9149(08)02117-6

doi:10.1016/j.amjcard.2008.11.042

American Journal of Cardiology
Volume 103, Issue 6 , Pages 867-871, 15 March 2009